R&D News | pharmaphorum

News

Sanofi, Merck’s Vaxelis is first six-in-one vaccine in US

Sanofi and Merck & Co picked up late 2018 approval from the FDA during the holiday period, getting a green light for their six-in-one paediatric shot Vaxelis.

News

PureTech's Vedanta raises $27m for microbiome research

US-based Vedanta Biosciences has raised $27 million in a Series C financing to investigate microbiome-derived therapies for several indications, including cancer and

News

Novartis offers to buy Kymriah manufacturer

Following its success in the burgeoning area of CAR-T therapies, Novartis is looking to strengthen its cell and gene manufacturing capabilities by offering t

News

Merck takes a back seat on CAR-T, handing assets to Intrexon

Merck KGaA wants to get bigger in immuno-oncology, but from now on it won’t be taking a direct role in the drive to develop new CAR-T therapies.

News

BMS confirms Taisho’s $1.6bn offer for UPSA

After protracted speculation, Bristol-Myers Squibb has confirmed it plans to divest its French over-the-counter (OTC) medicines business UPSA to Japan’s Taisho Pharma in a $1.6 billion deal

News

Pharma R&D productivity hits new low amid rising costs

Returns on pharma R&D investment are at a nine-year low, and the cost of developing a drug has nearly doubled since 2010, according to Deloitte’s yearly assessment of the industry’s pip

Sanofi, Merck’s Vaxelis is first six-in-one vaccine in US

PureTech's Vedanta raises $27m for microbiome research

Novartis offers to buy Kymriah manufacturer

Merck takes a back seat on CAR-T, handing assets to Intrexon

BMS confirms Taisho’s $1.6bn offer for UPSA

Pharma R&D productivity hits new low amid rising costs

Bayer plans filings for cardiac amyloidosis imaging agent

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks